Floatz logo

hs-20089

Ovarian Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
59/ 100

Competitive context

524 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Inno-206
Genmab
Phase 3BB
Carboplatin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

hs-20089 is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
endometrial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →